Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05295992 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Conventionally Fractionated Adaptive Radiation Therapy of Bladder Cancer an Individualized Approach

Study acronym: ARTIA-Vesica
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Mar 2024 to Dec 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Mar 2026 to Mar 2027
    • Site details revised
    v5
  2. Re-verified, no change to tracked fieldsv4
  3. Study title expanded, about 3 wordsv3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 2022 to Mar 15, 2022
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for muscle invasive bladder cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT).
Trial Details
NCT Number NCT05295992
Lead Sponsor Varian, a Siemens Healthineers Company
Collaborators: Herlev Hospital, Rigshospitalet, Denmark
Conditions
(from sponsor)		 Muscle-Invasive Bladder Carcinoma
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov